Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Pancreatic β cells secrete insulin in response to glucose elevation to maintain glucose homeostasis. A complex network of inter-organ communication operates to modulate insulin secretion and regulate glucose levels after a meal. Lipids obtained from diet or generated intracellularly are known to amplify glucose-stimulated insulin secretion, however, the underlying mechanisms are not completely understood. Here, we show that a Drosophila secretory lipase, Vaha (CG8093), is synthesized in the midgut and moves to the brain where it concentrates in the insulin-producing cells in a process requiring Lipid Transfer Particle, a lipoprotein originating in the fat body. In response to dietary fat, Vaha stimulates insulin-like peptide release (ILP), and Vaha deficiency results in reduced circulatory ILP and diabetic features including hyperglycemia and hyperlipidemia. Our findings suggest Vaha functions as a diacylglycerol lipase physiologically, by being a molecular link between dietary fat and lipid amplified insulin secretion in a gut-brain axis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11116528PMC
http://dx.doi.org/10.1038/s41467-024-48851-8DOI Listing

Publication Analysis

Top Keywords

insulin secretion
16
dietary fat
8
insulin
5
nutrient responsive
4
responsive lipase
4
lipase mediates
4
mediates gut-brain
4
gut-brain communication
4
communication regulate
4
regulate insulin
4

Similar Publications

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia and associated with severe complications, including cardiovascular diseases, neuropathy, nephropathy, and retinopathy. Although synthetic antidiabetic drugs are available, the side effects and limited long-term effectiveness of these medications highlight the urgent need for safer, more potent alternative therapies. L.

View Article and Find Full Text PDF

Pancreatic Islet Cell Hormones: Secretion, Function, and Diabetes Therapy.

MedComm (2020)

September 2025

Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, Division of Pancreatic Surgery, Department of General Surgery, Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, West China Hospital Sichuan University Chen

The pancreatic islets of Langerhans, which are composed of α, β, δ, ε, and PP cells, orchestrate systemic glucose homeostasis through tightly regulated hormone secretion. Although the precise mechanisms involving β cells in the onset and progression of diabetes have been elucidated and insulin replacement therapy remains the primary treatment modality, the regulatory processes, functions, and specific roles of other pancreatic islet hormones in diabetes continue to be the subject of ongoing investigation. At present, a comprehensive review of the secretion and regulation of pancreatic islet cell hormones as well as the related mechanisms of diabetes is lacking.

View Article and Find Full Text PDF

Background: The programmed cell death protein 1 (PDCD1 or PD-1) is a key regulatory immune checkpoint and a major target for therapeutic intervention. In oncology, antibodies blocking the PD-1 pathway are used to activate immune cells to promote anti tumour immunity while in immune-mediated inflammatory diseases, PD-1 agonist molecules have the potential to achieve immune suppression. NK cells are a specialised population of innate lymphocytes able to recognize a large range of distressed cells including damaged tissues in autoimmune and inflammatory conditions.

View Article and Find Full Text PDF

Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome resulting from excessive secretion of pro-insulin-like growth factor 2 (proIGF-2). This leads to hypoinsulinemic hypoglycemia and, in some cases, acromegaly. We report the case of a 52-year-old woman with NICTH syndrome who had decreased levels of insulin-like growth factor 1 (IGF1), insulin, C-peptide, and growth hormone (GH).

View Article and Find Full Text PDF

The conventional "one-size-fits-all" approach to treating and managing type 2 diabetes mellitus (T2DM) has proven challenging. T2DM is a complex, heterogeneous disease and frequently coexists with other conditions like hypertension, obesity, and dyslipidemia, further complicating treatment decisions and outcomes. While advances in diabetes medications have been made, traditional treatment algorithms often focus on broad glycemic targets, neglecting the diverse needs of patients with different risk profiles associated with ethnicity, comorbidities, and preferences.

View Article and Find Full Text PDF